Yavuz SALİHOĞLU, Hamdullah SÖZEN, Ahmet Cem İYİBOZKURT

DÜŞÜK DERECELİ ENDOMETRİYAL STROMAL SARKOMLARDA LENF NODU METASTAZI VE REKÜRRENS

Amaç: Bu retrospektif çalışmanın amacı, kliniğimizde opere edilmiş düşük dereceli endometrial stromal sarkom olgularında lenfatik yayılım deneyimimizi paylaşmak ve rekurrens şeklini araştırmaktır. Hastalar ve Yöntem: Kliniğimizde Ağustos 2001 ile Kasım 2011 arasında düşük dereceli endometriyal stromal sarkom nedeniyle opere edilmiş 14 olgu retrospektif olarak ele alındı. Yüm hastalara histerektomi yapıldı, ancak 6 hastaya pelvik ve/veya paraaortik lenfadenektomi yapıldı (% 43). Üç hasta takip sürecinden ayrıldı. Ortalama takip süresi 51 ay idi. Bulgular: 3 hastada lenfatik tutulum mevcuttu (%50). 11 takipli hastadan 2’sinde ekstrauterin tutulum saptandı (%18). İlk cerrahinin suboptimal olmasından dolayı, 3 hastada (%21) ikinci kez operasyona gereksinim oldu. Sonuç: Bu bulgular göstermektedir ki; düşük dereceli endometrial stromal sarkomlarda lenf nodu insidansı beklenenden daha fazladır. Daha geniş lenf nodu örneklemeleri veya daha fazla hastada lenfadenektomi sonuçları ile daha anlamlı sonuca varılabilir.

Anahtar Kelimeler:

Endometriyal stromal sarkom, lenf nodu metastazı

LYMPH NODE METASTASES AND PATTERNS OF RECURRENCE IN LOW-GRADE ENDOMETRIAL STROMAL SARCOMA

Objective: The purpose of this retrospective study is to investigate recurrence patterns and review our experience on lmyphatic dissemination in patients with low-grade endometrial stromal sarcoma. Study design: A retrospective review yielded 14 patients with ESS (all of them low-grade) who underwent primary surgical resection from August 2001 to November 2011. All patients underwent hysterectomy, whereas pelvic and/or paraaortic lymphadenectomy were performed in 6 patients (43%). Three of these patients had lack of follow-up. Median follow-up time was 51 months. Results: Lymphatic disease was noted in 3 patients (50%). Extrauterine recurrence was identified in 2 patients out of 11 full followup patients (18%). As the primary surgery was suboptimal, 3 patients (21%) were underwent secondary staging surgery. Conclusion: These findings suggest that the incidence of lymph node involvement in low-grade ESS is higher than expected. More extensive sampling of lymph nodes or complete lymphadenectomy in a larger number of patients may allow a better understanding of the frequency of lymph node involvement in low-grade ESS

Keywords:

Endometrial stromal sarcoma, lymph node metastases,

PDF

___

1. Norris HJ Taylor HB. Mesendnymal tumors of uterus. A clinical and pathologis study of 53 endometrial stromal tumors. Cancer. 1966; 19: 755-766
2. Chang KL, Crabtree GS, Lim-Tan SK. Primary uterine endometrial stromal neoplasms. A clinicopathology study of 117 cases. Am J Surg Pathol 1990; 14: 415-38
3. Golf BA, Rice LW, Flelschhacker D, et al. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol. 1993; 50: 105-109
4. Riopel J, Plante M, Renaud MC, et al. Lymph node metastases low-grade endometrial stromal sarcoma. Gynecol Oncol. 2005; 96: 402-406
5. Rose PG, Piver MS, Tsukada Y, Lau T. Patterns of metastasis in uterine sarcoma. An Autopsy study. Cancer. 1989; 63: 635-8
6. The National Cancer Institute. Available at: http//www. cancer.gov/cancertopics/pdq/treatement/Uterinesarcoma/ HealthProfessional. Accessed September 10, 2011.
7. Leath CA 3rd, Huh WK, Hyde J Jr, et al. a multiinstitutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol. 2007; 105: 630-634
8. El Husseiny G, Al Bareedy U, Mourad WA, Mohamed G, Shoukri M, Subhi J, et al. Prognostic factors and treatement modalities in uterine sarcoma. Am J Clin Oncol. 2002; 25: 256-60
9. Golf BA, Rice LW, Flelschhacker D, Muntz HG, Falkanberry SS, Nikrui N, et al. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol. 1993; 50: 105-9
10. Ayhan A, Tuncer ZS, Tanir M, Yuce K, Ayhan A. Uterine sarcoma, the Hacettepe Hospital experience of 88 consecutive patients. Eur J gynecol Oncol. 1997; 18: 146-8